News Headlines

31. Wombat Capital Markets Advised Regis Technologies On Its Sale To Esteve 9/26/2025

    This strategic move allows ESTEVE CDMO a physical presence in the U.S., expanding its contract development and manufacturing solutions for innovative small-molecule APIs across the entire drug development lifecycle from pre-clinical to commercial manufacturing.

32. Amgen Announces $650M Expansion Of U.S. Manufacturing, Creating Hundreds Of New JobS 9/26/2025

    Amgen (NASDAQ: AMGN) today announced a $650 million expansion of its U.S. manufacturing network, creating hundreds of new jobs.

33. Praxis Packaging Solutions Expands With Acquisition Of Advanced Concept Innovations, LLC 9/25/2025

    The strategic combination with ACI further enhances Praxis’ customer oPering by broadening Praxis’ geographic footprint into the Southeastern United States, expanding its capabilities and market segments.

34. Avant Technologies, Inc. Bolsters Strategic Vision With Targeted Biotech Partnerships For Innovative Cell-Based Therapies 9/25/2025

    Avant Technologies Inc. (OTCQB: AVAI) ("Avant" or the "Company"), today announced a pivotal evolution in its business direction, emphasizing strategic partnerships through joint ventures and licensing agreements to advance treatments for a range of chronic and age-related conditions.

35. New Partnership Brings Next-Generation Cell Isolation Solutions To Researchers Advancing Cell And Gene Therapy Development 9/25/2025

    Cayman Chemical, a global provider of life science research tools, and Akadeum Life Sciences, a leader in buoyancy-based cell separation technology, announced today a distribution partnership to expand access to Akadeum's next-generation cell isolation technology for cell and gene therapy development.

36. Verismo Therapeutics Announces Partnership With Miltenyi Biotec To Support Advancing Clinical Programs 9/25/2025

    Verismo Therapeutics, a clinical-stage CAR T company developing a novel KIR-CAR platform technology, today announced the successful manufacture of its first clinical cell product using lentiviral vector supplied by Miltenyi Bioindustry, a dedicated CDMO division of Miltenyi Biotec.

37. Bora Biologics To Manufacture NYPOZI At San Diego Facility In Partnership With InvaGen Pharmaceuticals, A Cipla Group Company 9/25/2025

    Bora Biologics, a leading contract development and manufacturing organization (CDMO) specializing in biologics, proudly announces its partnership with InvaGen Pharmaceuticals Inc., a wholly owned subsidiary of Cipla Limited, for the manufacture of NYPOZI (biosimilar to Neupogen) at its FDA-registered facility in San Diego, California.

38. WuXi Biologics Launches WuXia™4.0, Targeted Integration Cell Line Platform TrueSite TI™ To Accelerate Biologics Development With High Titer And Superior Stability 9/25/2025

    WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of TrueSite TI™, an industry-leading targeted integration (TI)-based CHO cell line platform designed to reshape biologics development by accelerating timelines, enhancing product quality, and ensuring consistent scalability for antibody and complex protein therapies.

39. ITM And TerThera Sign Supply Agreement For Medical Radioisotope Terbium-161 9/24/2025

    ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and TerThera BV, a leading provider of GMP-grade Terbium-161, today announced a supply agreement for non-carrier-added (n.c.a.) Terbium-161 (Tb-161), a novel medical radioisotope with distinct chemical properties and emerging potential in radiopharmaceutical therapy.

40. Leading CDMO Enhances cGMP Lab Infrastructure To Strengthen Position 9/24/2025

    The Ritedose Corporation is investing more than $17 million to further its in-house cGMP laboratory capabilities by expanding its analytical chemistry and microbiology laboratories.